Stargardt Clinical Trials

26 recruitingLast updated: July 25, 2026

There are 26 actively recruiting stargardt clinical trials across 8 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3. Top locations include Dallas, Texas, United States, Boston, Massachusetts, United States, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Stargardt Trials at a Glance

26 actively recruiting trials for stargardt are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Dallas, Boston, and Ann Arbor. Lead sponsors running stargardt studies include National Eye Institute (NEI), Ray Therapeutics, Inc., and Ascidian Therapeutics, Inc.

Browse stargardt trials by phase

Treatments under study

About Stargardt Clinical Trials

Looking for clinical trials for Stargardt? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stargardt trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stargardt clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Stargardt DiseaseStargardt-Like Macular DystrophyStargardt Macular Dystrophy
Astellas Pharma Global Development, Inc.90 enrolled12 locationsNCT07425574
Recruiting

Rod and Cone Mediated Function in Retinal Disease

Stargardt's DiseaseRetinal DegenerationRetinitis Pigmentosa
National Eye Institute (NEI)500 enrolled1 locationNCT02617966
Recruiting
Phase 3

Study of ALK-001 on the Progression of Stargardt Disease

Stargardt Disease
Alkeus Pharmaceuticals, Inc.230 enrolled5 locationsNCT07419334
Recruiting
Not Applicable

Stem Cell Ophthalmology Treatment Study II

Age-Related Macular DegenerationRetinitis PigmentosaMacular Degeneration+15 more
MD Stem Cells500 enrolled4 locationsNCT03011541
Recruiting
Phase 1Phase 2

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

Stargardt Disease
AAVantgarde Bio Srl75 enrolled8 locationsNCT07161544
Recruiting
Phase 1

Phase 1 Study of C.001 in Retinal Degeneration

Geographic AtrophyAge-Related Macular DegenerationStargardt Disease+1 more
Cellio Therapeutics Inc15 enrolled1 locationNCT07594236
Recruiting

Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Stargardt-Like Macular Dystrophy
National Eye Institute (NEI)25 enrolled1 locationNCT04591483
Recruiting

Inherited Retinal Degenerative Disease Registry

Retinitis PigmentosaBatten DiseaseLeber Congenital Amaurosis+25 more
Foundation Fighting Blindness20,000 enrolled1 locationNCT02435940
Recruiting
Phase 1Phase 2

Oral Metformin for Treatment of ABCA4 Retinopathy

Retinal DegenerationRetinal DystrophyStargardt Disease+1 more
National Eye Institute (NEI)56 enrolled2 locationsNCT04545736
Recruiting

High Resolution Retinal Imaging

Geographic AtrophyAge-Related Macular DegenerationRetinitis Pigmentosa+2 more
University of Pennsylvania600 enrolled1 locationNCT01866371
Recruiting
Phase 1Phase 2

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Stargardt Disease
Ray Therapeutics, Inc.18 enrolled3 locationsNCT07439887
Recruiting
Early Phase 1

The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4

Stargardt
Zhongshan Ophthalmic Center, Sun Yat-sen University9 enrolled2 locationsNCT07241169
Recruiting
Not Applicable

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Retinitis pigmentosa (RP)Stargardt DiseaseInherited Retinal Degeneration
Science Corporation5 enrolled1 locationNCT07266584
Recruiting

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

X-linked RetinoschisisRetinitis PigmentosaStargardt Disease+3 more
Ray Therapeutics, Inc.25 enrolled1 locationNCT07502664
Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Stargardt DiseaseStargardt Disease 1Cone-Rod Dystrophy+1 more
Ascidian Therapeutics, Inc50 enrolled8 locationsNCT06445322
Recruiting
Phase 1

A Study of DC6001 Tablet in Healthy Chinese Adult Subjects

Stargardt Disease
Heronova Pharmaceuticals76 enrolled1 locationNCT07417566
Recruiting
Phase 1Phase 2

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
VeonGen Therapeutics GmbH15 enrolled1 locationNCT07002398
Recruiting
Phase 1Phase 2

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Stargardt DiseaseStargardt Disease 1Cone-Rod Dystrophy+1 more
Ascidian Therapeutics, Inc15 enrolled10 locationsNCT06467344
Recruiting
Phase 2Phase 3

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Stargardt Disease
Ocugen51 enrolled14 locationsNCT05956626
Recruiting
Phase 1

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Age-Related Macular DegenerationAlcohol Use DisorderRetinitis Pigmentosa+2 more
University of Rochester15 enrolled1 locationNCT06319872